A three-chemical cocktail, distinct from complex gene therapies, has been shown to rejuvenate brain organoids and is being prepared for Phase 1 human trials. The treatment is designed to be taken as a simple oral pill, drastically increasing its potential accessibility and ease of use.

Despite its name suggesting a link to the pineal gland, the tripeptide Pinealon (EDR) was actually isolated from a brain cortex extract called Cortexin. It was developed by Soviet researchers not for sleep, but as an anti-stress and cognitive performance compound for soldiers and astronauts.

Yamanaka factors—proteins that can reverse cellular age—are entering their first FDA-approved human clinical trial. The study will deliver the proteins into the eyes of patients to rejuvenate retinal cells and restore vision, marking a milestone for regenerative medicine.

Brief, daily exposure to 670nm red light rejuvenates aging retinal cells by improving mitochondrial function. In studies on individuals over 40, this non-invasive therapy restored age-related visual acuity decline by as much as 22%.

A new wave of therapies for Stargardt disease is moving beyond simply slowing progression. Approaches like optogenetics aim to restore vision even in advanced patients by creating new light-sensing capabilities in retinal cells, bypassing the photoreceptors already lost to the disease.

Contrary to the long-held belief that nerves don't regrow, scientists have achieved 100% regeneration of crushed optic nerves in mice, restoring their sight. This groundbreaking success, far surpassing previous 5% regrowth rates, opens the door to treating spinal cord injuries and neurodegenerative diseases like ALS.

Many biological processes like hormone regulation and mood are triggered by light hitting non-visual melanopsin cells in the retina. Blind people who still have their eyes can activate these powerful health pathways through light exposure.

Reversing the age of a mouse retina surprisingly caused the spontaneous clearance of protein buildups associated with macular degeneration. This suggests that restoring a cell's youthful epigenetic state also reactivates its innate ability to clean and repair itself, a promising sign for treating diseases like Alzheimer's.

CEO Lance Baldo suggests that gene therapy in the eye is uniquely positioned for success. As an encapsulated organ with "immune privilege," the eye reduces risks like hepatotoxicity seen in systemic therapies. This creates a safer environment to generate learnings that can then be applied to advance gene therapies for other organs.